SpyGlass Pharma, Inc.
SGP · XNASCIK 1778922fmd_0CC35GYCFH88185S13RD18D34ZManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 8 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 20 | 29 |
| Total operating expenses | 27 | 41 |
| Operating income | (27) | (41) |
| Interest and investment income | 1 | 3 |
| Other non-operating income (expense) | (2) | 2 |
| Income before taxes | (29) | (40) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (29) | (40) |
| Net income | (29) | (40) |